drugset / Trial / NCT00504127

Efficacy and Safety Study of Naproxcinod in Subjects With Osteoarthritis of the Knee

NCT00504127

Phase 3 Completed 1020 enrolled NicOx
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To study of efficacy and safety of Naproxcinod vs. Naproxen and Placebo in the indication of signs and symptoms of osteoarthritis

Timeline

Start
2007-04
Primary completion
2008-12
Completion

Drugs

EvaluationDrugModalityDoseRoute
Comparator Naproxen Small molecule 500 mg
Subject naproxcinod Other / unclassified 375 mg
Subject naproxcinod Other / unclassified 750 mg

Indications